New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was 0.00% in Q3 FY26, the highest of these four quarters.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE−113.8%−128.9%−169.1%−212.3%
ROIC0.0%0.0%0.0%0.0%

Debt

Net debt is 4.08× a year’s EBITDA. Debt is 0.00× equity.

Debt / equityNet debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Debt / equity0.0×0.0×0.0×0.0×
Net debt / EBITDA3.4×4.1×2.9×4.1×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Current Ratio

+8 more quarters

2.07 1.73 1.22 1.00
Net Debt/EBITDA
3.39 4.11 2.93 4.08
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(2.04) (4.04) (2.86) (1.24)
Book value per Share
5.91 3.67 1.39 0.02
Free Cash Flow
(6.48) (12.97) (9.18) (3.99)
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 12, 2026